About FV-100 Published surrounded using vitro study particular demonstrated that FV-100, a bicylcic nucleoside analogue, be more potent antagonistic and can inhibit the replication of VZV substantially faster than other antiviral therapeutics now qualified in shop at of the attention of shingles. Inhibitex believe these characteristics pigs the promise for FV-100 to soften the regularity and roughness of shingles-related symptom, plus acute headache and PHN.
About Inhibitex Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical enterprise positive against embryonic products to delight and prevention reflective contagious bug. In tally to FV-100, the Company's foundation pipeline include a phase of HCV nucleoside polymerase inhibitors and HIV integrase inhibitors. Inhibitex have also licensed its proprietary MSCRAMM® protein technology to Wyeth for the development of staphylococcal vaccines and to 3M for the development of diagnostics.
For extra gossip in the order of the Company, satisfy call in Safe Harbor Statement This switch permit saggy enclose forward-looking statement in the gist of the Private Securities Litigation Reform Act of 1995 that confuse near sizeable hazard and uncertainties. All statements, handrail statements of historical facts, including those associated to the potential for FV-100 to be dose once-a-day and to further reduce the incidence and severity of shingles-related symptoms, including the incidence and severity of acute pain and PHN; the Company's huddle to total the Phase I MAD audition in the fourth quarter; the Company's plan to initiate a Phase II clinical trial of FV-100 in shingles patients nigh on the new building of 2008; and the Company's procedure to uncultured the overflowing facts from the Phase I SAD trial at ICAAC in the discharge be forward-looking statements. These plans, intention, expectations, or juncture estimate may not truly be engage in and sundry celebrated factor could put up develop actual grades or communication to hostilities materially from the forward-looking statements that the Company make, including risks that the results of wished-for preclinical and clinical studies may not spinal column up and about prior findings or support the further development of FV-100; the Company not self competent to enroll patients in its clinical trial in a timely air; the Company not get your hands on regulatory passion to mortgage the development of FV-100; any the Company, the U.S. Food and Drug Administration (FDA) or an investigational study sheet (IRB) suspend or terminate the clinical development of FV-100 for sanctuary or other cause; FV-100 not prove to be efficacious in reducing shingles-related symptoms in patients in future clinical trials and other looming statements contained elsewhere herein and in its Annual Report on Form 10-K for the year concluded December 31, 2007, in slot of file with the Securities and Exchange Commission, or SEC, on March 14, 2008, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 as filed with the SEC on May 9, 2008. Given these uncertainties, you should not place undue hope on these forward-looking statements, which apply singular commencing the date of this press release.
There may be events in the future that the Company is powerless to divine accurately, or complete which it has no lead. The Company's company, fiscal qualification, results of operation and prospects may metamorphose. The Company may not update these forward-looking statements, even nonetheless its importance may change in the future, unless it has obligation humiliate than the Federal securities tenet to update and unburden your heart to fabric development related to in former times disclose information. The Company qualify all of the information contained here press release, and markedly its forward-looking statements, by these cautionary statements.
Inhibitex® and MSCRAMM® are register trademark of Inhibitex, Inc.
Inhibitex, Inc.
Challenging... where to buy pills? Buy allegra 60 pills online, it is a good way to save.
online pharmacy shipping policy - tabletsguide now
Keine Kommentare:
Kommentar veröffentlichen